|
MechanismEPHA4 modulators |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Intravenous ORT247 in Healthy Volunteers
This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of escalating intravenous doses of ORT247 in healthy volunteers.
100 Clinical Results associated with Orthogonal Neuroscience Inc.
0 Patents (Medical) associated with Orthogonal Neuroscience Inc.
100 Deals associated with Orthogonal Neuroscience Inc.
100 Translational Medicine associated with Orthogonal Neuroscience Inc.